This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Group, f. T. S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Group, f. T. S. P.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 1998, p. 1886-1889, Vol. 36, No. 7
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and Antifungal Susceptibilities of Isolates Collected in 1997 in the United States, Canada, and South America for the SENTRY Program

M. A. Pfaller,1,* R. N. Jones,1 G. V. Doern,1 H. S. Sader,2 R. J. Hollis,1 S. A. Messer,1 and for The Sentry Participant Group

Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa,1 and Division of Infectious Diseases, Universidade Federal de Sao Paulo/EPM, Sao Paulo, Brazil2

Received 9 February 1998/Returned for modification 2 March 1998/Accepted 3 April 1998

An international program of surveillance of bloodstream infections (BSIs) in the United States, Canada, and South America between January and December 1997 detected 306 episodes of candidemia in 34 medical centers (22 in the United States, 6 in Canada, and 6 in South America). Eighty percent of the BSIs were nosocomial and 50% occurred in patients hospitalized in an intensive care unit. Overall, 53.3% of the BSIs were due to Candida albicans, 15.7% were due to C. parapsilosis, 15.0% were due to C. glabrata, 7.8% were due to C. tropicalis, 2.0% were due to C. krusei, 0.7% were due to C. guilliermondii, and 5.8% were due to Candida spp. However, the distribution of species varied markedly by country. In the United States, 43.8% of BSIs were due to non-C. albicans species. C. glabrata was the most common non-C. albicans species in the United States. The proportion of non-C. albicans BSIs was slightly higher in Canada (47.5%), where C. parapsilosis, not C. glabrata, was the most common non-C. albicans species. C. albicans accounted for 40.5% of all BSIs in South America, followed by C. parapsilosis (38.1%) and C. tropicalis (11.9%). Only one BSI due to C. glabrata was observed in South American hospitals. Among the different species of Candida, resistance to fluconazole (MIC, >= 64 µg/ml) and itraconazole (MIC, >= 1.0 µg/ml) was observed with C. glabrata and C. krusei and was observed more rarely among other species. Isolates of C. albicans, C. parapsilosis, C. tropicalis, and C. guilliermondii were all highly susceptible to both fluconazole (99.4 to 100% susceptibility) and itraconazole (95.8 to 100% susceptibility). In contrast, 8.7% of C. glabrata isolates (MIC at which 90% of isolates are inhibited [MIC90], 32 µg/ml) and 100% of C. krusei isolates were resistant to fluconazole, and 36.9% of C. glabrata isolates (MIC90, 2.0 µg/ml) and 66.6% of C. krusei isolates were resistant to itraconazole. Within each species there were no geographic differences in susceptibility to fluconazole or itraconazole.

* Corresponding author. Mailing address: Medical Microbiology Division, Department of Pathology, C606 GH, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 384-9566. Fax: (319) 356-4916. E-mail: mpfaller{at}blue.weeg.uiowa.edu.

Journal of Clinical Microbiology, July 1998, p. 1886-1889, Vol. 36, No. 7
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Trofa, D., Gacser, A., Nosanchuk, J. D. (2008). Candida parapsilosis, an Emerging Fungal Pathogen. Clin. Microbiol. Rev. 21: 606-625 [Abstract] [Full Text]  
  • Gonzalez, G. M., Elizondo, M., Ayala, J. (2008). Trends in Species Distribution and Susceptibility of Bloodstream Isolates of Candida Collected in Monterrey, Mexico, to Seven Antifungal Agents: Results of a 3-Year (2004 to 2007) Surveillance Study. J. Clin. Microbiol. 46: 2902-2905 [Abstract] [Full Text]  
  • Dimopoulos, G., Ntziora, F., Rachiotis, G., Armaganidis, A., Falagas, M. E. (2008). Candida Albicans Versus Non-Albicans Intensive Care Unit-Acquired Bloodstream Infections: Differences in Risk Factors and Outcome. Anesth. Analg. 106: 523-529 [Abstract] [Full Text]  
  • Fleck, R., Dietz, A., Hof, H. (2007). In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother 59: 767-771 [Abstract] [Full Text]  
  • Colombo, A. L., Nucci, M., Park, B. J., Nouer, S. A., Arthington-Skaggs, B., da Matta, D. A., Warnock, D., Morgan, J., for the Brazilian Network Candidemia Study, (2006). Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers.. J. Clin. Microbiol. 44: 2816-2823 [Abstract] [Full Text]  
  • Girmenia, C., Pizzarelli, G., Cristini, F., Barchiesi, F., Spreghini, E., Scalise, G., Martino, P. (2006). Candida guilliermondii Fungemia in Patients with Hematologic Malignancies.. J. Clin. Microbiol. 44: 2458-2464 [Abstract] [Full Text]  
  • Fujita, S.-i., Takamura, T., Nagahara, M., Hashimoto, T. (2006). Evaluation of a newly developed down-flow immunoassay for detection of serum mannan antigens in patients with candidaemia.. J Med Microbiol 55: 537-543 [Abstract] [Full Text]  
  • Fridkin, S. K., Kaufman, D., Edwards, J. R., Shetty, S., Horan, T., the National Nosocomial Infections Surveillance Sy, (2006). Changing Incidence of Candida Bloodstream Infections Among NICU Patients in the United States: 1995-2004. Pediatrics 117: 1680-1687 [Abstract] [Full Text]  
  • Messer, S. A., Diekema, D. J., Boyken, L., Tendolkar, S., Hollis, R. J., Pfaller, M. A. (2006). Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp.. J. Clin. Microbiol. 44: 324-326 [Abstract] [Full Text]  
  • Olson, J. A., Adler-Moore, J. P., Smith, P. J., Proffitt, R. T. (2005). Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin. Antimicrob. Agents Chemother. 49: 4895-4902 [Abstract] [Full Text]  
  • Morrell, M., Fraser, V. J., Kollef, M. H. (2005). Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality. Antimicrob. Agents Chemother. 49: 3640-3645 [Abstract] [Full Text]  
  • Kayingo, G., Wong, B. (2005). The MAP kinase Hog1p differentially regulates stress-induced production and accumulation of glycerol and D-arabitol in Candida albicans. Microbiology 151: 2987-2999 [Abstract] [Full Text]  
  • Sanchez-Vargas, L. O., Ortiz-Lopez, N. G., Villar, M., Moragues, M. D., Aguirre, J. M., Cashat-Cruz, M., Lopez-Ribot, J. L., Gaitan-Cepeda, L. A., Quindos, G. (2005). Oral Candida Isolates Colonizing or Infecting Human Immunodeficiency Virus-Infected and Healthy Persons in Mexico. J. Clin. Microbiol. 43: 4159-4162 [Abstract] [Full Text]  
  • Golan, Y. (2005). Overview of transplant mycology. Am J Health Syst Pharm 62: S17-S21 [Abstract] [Full Text]  
  • Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., Fadda, G. (2005). Mechanisms of Azole Resistance in Clinical Isolates of Candida glabrata Collected during a Hospital Survey of Antifungal Resistance. Antimicrob. Agents Chemother. 49: 668-679 [Abstract] [Full Text]  
  • Carver, P. L (2004). Micafungin. The Annals of Pharmacotherapy 38: 1707-1721 [Abstract] [Full Text]  
  • Kaur, R., Castano, I., Cormack, B. P. (2004). Functional Genomic Analysis of Fluconazole Susceptibility in the Pathogenic Yeast Candida glabrata: Roles of Calcium Signaling and Mitochondria. Antimicrob. Agents Chemother. 48: 1600-1613 [Abstract] [Full Text]  
  • Warn, P. A., Sharp, A., Guinea, J., Denning, D. W. (2004). Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. J Antimicrob Chemother 53: 743-749 [Abstract] [Full Text]  
  • Takakura, S., Fujihara, N., Saito, T., Kudo, T., Iinuma, Y., Ichiyama, S., the Japan Invasive Mycosis Surveillance Study Grou, (2004). National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 53: 283-289 [Abstract] [Full Text]  
  • Onyewu, C., Blankenship, J. R., Del Poeta, M., Heitman, J. (2003). Ergosterol Biosynthesis Inhibitors Become Fungicidal when Combined with Calcineurin Inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. 47: 956-964 [Abstract] [Full Text]  
  • Dostal, J., Hamal, P., Pavlickova, L., Soucek, M., Ruml, T., Pichova, I., Hruskova-Heidingsfeldova, O. (2003). Simple Method for Screening Candida Species Isolates for the Presence of Secreted Proteinases: a Tool for the Prediction of Successful Inhibitory Treatment. J. Clin. Microbiol. 41: 712-716 [Abstract] [Full Text]  
  • Yang, C. W., Barkham, T. M. S., Chan, F. Y., Wang, Y. (2003). Prevalence of Candida Species, Including Candida dubliniensis, in Singapore. J. Clin. Microbiol. 41: 472-474 [Abstract] [Full Text]  
  • Safdar, A., Chaturvedi, V., Koll, B. S., Larone, D. H., Perlin, D. S., Armstrong, D. (2002). Prospective, Multicenter Surveillance Study of Candida glabrata: Fluconazole and Itraconazole Susceptibility Profiles in Bloodstream, Invasive, and Colonizing Strains and Differences between Isolates from Three Urban Teaching Hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999). Antimicrob. Agents Chemother. 46: 3268-3272 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2002). Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility. J. Clin. Microbiol. 40: 3551-3557 [Full Text]  
  • Asmundsdottir, L. R., Erlendsdottir, H., Gottfredsson, M. (2002). Increasing Incidence of Candidemia: Results from a 20-Year Nationwide Study in Iceland. J. Clin. Microbiol. 40: 3489-3492 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Rodero, L., Garcia-Effron, G., Rodriguez-Tudela, J. L. (2002). Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother 49: 981-987 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Diekema, D. J. (2002). In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp.. Antimicrob. Agents Chemother. 46: 1723-1727 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N. (2002). Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46: 1032-1037 [Abstract] [Full Text]  
  • Rustad, T. R., Stevens, D. A., Pfaller, M. A., White, T. C. (2002). Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology 148: 1061-1072 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A., Hollis, R. J. (2002). Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40: 852-856 [Abstract] [Full Text]  
  • Chryssanthou, E. (2001). Trends in Antifungal Susceptibility among Swedish Candida Species Bloodstream Isolates from 1994 to 1998: Comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A Reference Method. J. Clin. Microbiol. 39: 4181-4183 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., The SENTRY Participant Group, (2001). International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol. 39: 3254-3259 [Abstract] [Full Text]  
  • Weig, M., Haynes, K., Rogers, T. R., Kurzai, O., Frosch, M., Muhlschlegel, F. A. (2001). A GAS-like gene family in the pathogenic fungus Candida glabrata. Microbiology 147: 2007-2019 [Abstract] [Full Text]  
  • Safdar, A., Chaturvedi, V., Cross, E. W., Park, S., Bernard, E. M., Armstrong, D., Perlin, D. S. (2001). Prospective Study of Candida Species in Patients at a Comprehensive Cancer Center. Antimicrob. Agents Chemother. 45: 2129-2133 [Abstract] [Full Text]  
  • Sugita, T., Ichikawa, T., Matsukura, M., Sueda, M., Takashima, M., Ikeda, R., Nishikawa, A., Shinoda, T. (2001). Genetic Diversity and Biochemical Characteristics of Trichosporon asahii Isolated from Clinical Specimens, Houses of Patients with Summer-Type-Hypersensitivity Pneumonitis, and Environmental Materials. J. Clin. Microbiol. 39: 2405-2411 [Abstract] [Full Text]  
  • Niimi, K., Shepherd, M. G., Cannon, R. D. (2001). Distinguishing Candida Species by {beta}-N-Acetylhexosaminidase Activity. J. Clin. Microbiol. 39: 2089-2097 [Abstract] [Full Text]  
  • Santangelo, R., Paderu, P., Delmas, G., Chen, Z.-W., Mannino, R., Zarif, L., Perlin, D. S. (2000). Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model of Systemic Candidiasis. Antimicrob. Agents Chemother. 44: 2356-2360 [Abstract] [Full Text]  
  • Soll, D. R. (2000). The Ins and Outs of DNA Fingerprinting the Infectious Fungi. Clin. Microbiol. Rev. 13: 332-370 [Abstract] [Full Text]  
  • Tsuchimori, N., Sharkey, L. L., Fonzi, W. A., French, S. W., Edwards, J. E. Jr., Filler, S. G. (2000). Reduced Virulence of HWP1-Deficient Mutants of Candida albicans and Their Interactions with Host Cells. Infect. Immun. 68: 1997-2002 [Abstract] [Full Text]  
  • Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., The SENTRY Participant Group, (2000). Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. 44: 747-751 [Abstract] [Full Text]  
  • Provine, H., Hadley, S. (2000). Preliminary Evaluation of a Semisolid Agar Antifungal Susceptibility Test for Yeasts and Molds. J. Clin. Microbiol. 38: 537-541 [Abstract] [Full Text]  
  • Baran, J. Jr., Klauber, E., Barczak, J., Riederer, K., Khatib, R. (2000). Trends in Antifungal Susceptibility among Candida sp. Urinary Isolates from 1994 and 1998. J. Clin. Microbiol. 38: 870-871 [Abstract] [Full Text]  
  • Marco, F., Lockhart, S. R., Pfaller, M. A., Pujol, C., Rangel-Frausto, M. S., Wiblin, T., Blumberg, H. M., Edwards, J. E., Jarvis, W., Saiman, L., Patterson, J. E., Rinaldi, M. G., Wenzel, R. P., The Nemis Study Group, , Soll, D. R. (1999). Elucidating the Origins of Nosocomial Infections with Candida albicans by DNA Fingerprinting with the Complex Probe Ca3. J. Clin. Microbiol. 37: 2817-2828 [Abstract] [Full Text]  
  • Marr, K. A., Rustad, T. R., Rex, J. H., White, T. C. (1999). The Trailing End Point Phenotype in Antifungal Susceptibility Testing Is pH Dependent. Antimicrob. Agents Chemother. 43: 1383-1386 [Abstract] [Full Text]  
  • Hazen, K. C., Theisz, G. W., Howell, S. A. (1999). Chronic Urinary Tract Infection Due to Candida utilis. J. Clin. Microbiol. 37: 824-827 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Gee, S., Joly, S., Pujol, C., Sullivan, D. J., Coleman, D. C., Soll, D. R. (1999). In Vitro Susceptibilities of Candida dubliniensis Isolates Tested against the New Triazole and Echinocandin Antifungal Agents. J. Clin. Microbiol. 37: 870-872 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»